Ceftiofur (Spectramast LC)

Ceftiofur hydrochloride represents an advanced third-generation cephalosporin antibiotic specifically formulated for intramammary administration in lactating dairy cattle experiencing clinical mastitis. Marketed as Spectramast LC, this formulation delivers extended-spectrum antimicrobial activity directly to infected mammary tissue, providing coverage against both gram-positive and gram-negative pathogens that cause bovine intramammary infections. The third-generation cephalosporin classification reflects ceftiofur's enhanced stability against bacterial beta-lactamase enzymes and expanded gram-negative spectrum compared to earlier cephalosporin generations, making it particularly valuable for treatment of coliform mastitis caused by Escherichia coli and other Enterobacteriaceae that earlier-generation products may not adequately address.

The mechanism of action underlying ceftiofur's antimicrobial effect centers on irreversible inhibition of bacterial cell wall synthesis through binding to penicillin-binding proteins essential for peptidoglycan cross-linking. Like other beta-lactam antibiotics, ceftiofur interferes with the transpeptidation reactions that create the structural integrity of bacterial cell walls. The resulting inhibition produces mechanically weakened cell walls unable to withstand osmotic pressure, leading to bacterial cell lysis during active growth phases. Ceftiofur's molecular structure provides resistance to degradation by many beta-lactamase enzymes produced by resistant bacteria, extending its spectrum of activity to include organisms that would inactivate traditional penicillins or first-generation cephalosporins.

Spectramast LC is supplied as sterile single-dose intramammary infusion syringes designed for convenient administration during milking routines in commercial dairy operations. Each syringe delivers a precisely measured dose of ceftiofur hydrochloride in a formulation optimized for mammary gland distribution and antimicrobial activity. The product is typically administered at regular intervals following complete milk-out of the affected quarter, with treatment extending over multiple doses as specified on product labeling. The extended-spectrum activity provides coverage against the diverse range of pathogens encountered in clinical mastitis presentations, including both the gram-positive streptococci and staphylococci and the gram-negative coliforms that represent major mastitis challenges.

Regulatory approval for Spectramast LC has been established through FDA Center for Veterinary Medicine review, with specific labeling for treatment of clinical mastitis in lactating dairy cattle caused by susceptible organisms including both gram-positive and gram-negative pathogens. The product carries mandatory milk and meat withdrawal requirements designed to prevent antibiotic residues in foods derived from treated animals. Veterinary prescription is required, reflecting the importance of professional oversight in antimicrobial selection and the particular significance of extended-spectrum cephalosporins as critically important antimicrobials requiring judicious use. The product represents a significant therapeutic option for mastitis cases involving organisms resistant to narrower-spectrum alternatives.

The primary labeled indication for ceftiofur intramammary infusion encompasses treatment of clinical mastitis in lactating dairy cattle caused by susceptible strains of both gram-positive and gram-negative organisms. This broad indication reflects the extended spectrum of third-generation cephalosporin activity, which includes the streptococcal species responsible for contagious and environmental mastitis, coagulase-negative staphylococci, and critically, the Escherichia coli and other coliform bacteria that cause some of the most severe and economically significant mastitis presentations. Clinical mastitis suitable for Spectramast LC treatment presents with visible abnormalities in milk character and may include systemic signs in severe coliform cases.

Species-specific application of Spectramast LC is restricted to lactating dairy cattle presenting with clinical mastitis requiring broad-spectrum antimicrobial intervention. The product is indicated for dairy cows of all breeds during active lactation when clinical signs warrant antibiotic therapy and the pathogen profile suggests benefit from extended-spectrum coverage. Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and crossbred dairy cattle all demonstrate appropriate clinical response when causative organisms fall within the antimicrobial spectrum. The product's particular value lies in situations where gram-negative involvement is suspected or confirmed, distinguishing its application from narrower-spectrum alternatives that address primarily gram-positive pathogens.

Treatment of coliform mastitis represents a primary therapeutic target for ceftiofur lactating cow therapy. Escherichia coli is the predominant coliform mastitis pathogen and causes clinical presentations ranging from mild transient infection to severe toxic mastitis with systemic illness and potential mortality. While spontaneous cure of coliform mastitis occurs frequently, antimicrobial therapy may improve outcomes in selected cases, particularly when initiated early or when systemic involvement threatens cow survival. Ceftiofur's gram-negative activity provides appropriate coverage for E. coli and related Enterobacteriaceae including Klebsiella species that cause similar clinical presentations. The importance of supportive care concurrent with antimicrobial therapy for severe coliform mastitis cannot be overstated.

Streptococcal and staphylococcal mastitis treatment with ceftiofur provides effective coverage against the gram-positive pathogens that remain the most common overall cause of bovine mastitis. Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, and coagulase-negative staphylococci demonstrate good susceptibility to ceftiofur. The third-generation cephalosporin provides advantages against organisms producing certain beta-lactamase enzymes that would inactivate penicillins. However, methicillin-resistant staphylococci including MRSA strains are resistant to all beta-lactam antibiotics including ceftiofur, and treatment of such infections requires alternative approaches.

Extra-label applications of ceftiofur intramammary products should be approached with particular caution given the designation of third-generation cephalosporins as critically important antimicrobials for human medicine. Routine use for conditions where narrower-spectrum alternatives would be appropriate undermines antimicrobial stewardship principles. Extended treatment duration beyond label specifications may be considered under veterinary direction for difficult infections, though cure rates for chronic established infections remain challenging regardless of duration. Any extra-label use requires appropriate extended withdrawal time calculation, documentation within a valid VCPR, and careful consideration of antimicrobial stewardship implications.

Dosage of ceftiofur for lactating cow mastitis treatment follows label specifications calling for administration of one complete syringe per affected quarter at each dosing interval. Spectramast LC syringes deliver 125 milligrams of ceftiofur hydrochloride per dose in a formulation designed for intramammary administration. Label directions specify treatment administered once daily for two consecutive days for most mastitis presentations, though alternative protocols may be indicated on product labeling for specific situations. Treatment is restricted to affected quarters showing clinical mastitis signs rather than prophylactic treatment of unaffected quarters in the same cow unless multiple quarters are clinically involved.

The intramammary route of administration demands strict attention to aseptic technique to prevent introduction of additional pathogens into already-compromised mammary tissue. Prior to administration, the affected quarter must be completely milked out to remove abnormal secretions, bacteria, and inflammatory debris. This therapeutic milking reduces bacterial load and removes physical barriers to antibiotic distribution while providing diagnostic information through secretion examination. Thorough cleaning and disinfection of teat ends using alcohol-soaked cotton or gauze is essential before cannula insertion. The teat end should be allowed to dry briefly to prevent carrying residual disinfectant or surface contamination into the teat canal.

Treatment duration for ceftiofur lactating cow therapy typically spans two consecutive daily administrations according to label specifications, representing a shorter treatment course than many traditional mastitis therapy protocols. The pharmacokinetic properties of ceftiofur allow for once-daily dosing rather than administration at each milking, simplifying treatment logistics while maintaining therapeutic efficacy. Each treatment should be administered at approximately the same time each day to maintain consistent drug exposure. The relatively short treatment course combined with zero milk discard requirement during treatment represents significant practical advantages for dairy operations managing clinical mastitis cases.

Administration technique follows standard intramammary infusion protocols with attention to minimizing trauma and contamination. Following thorough teat end preparation, the syringe cannula should be partially inserted into the teat canal to a depth of approximately 2-3 millimeters using partial insertion technique. This approach minimizes damage to delicate teat end tissues and keratin-producing cells compared to full cannula insertion. Syringe contents should be infused with steady, gentle pressure while massaging the quarter to promote antibiotic distribution throughout the gland cistern. Following infusion, the teat should be dipped with post-milking germicidal teat dip as part of routine milking hygiene.

No milk discard during treatment represents a distinguishing feature of Spectramast LC when used according to label directions. Unlike most lactating cow intramammary antibiotics that require milk withholding throughout treatment and for a specified period afterward, ceftiofur hydrochloride intramammary infusion allows continued milk marketing during treatment provided the product is used according to labeled specifications. This zero-day milk withhold during treatment dramatically reduces the economic impact of mastitis therapy by eliminating discard of withdrawal milk. Meat withdrawal requirements remain in effect and must be observed should treated cows require emergency slaughter.

Withdrawal time requirements for ceftiofur hydrochloride intramammary infusion reflect the unique pharmacokinetic properties allowing for milk marketing during treatment. While milk from treated cows can enter the bulk tank during treatment according to label specifications, meat withdrawal times apply to any treated animal potentially entering slaughter channels. The labeled meat withdrawal for Spectramast LC must be strictly observed. Treatment records must document animal identification, product used, treatment dates, and calculated meat withdrawal to ensure compliance. The zero milk discard feature does not eliminate the need for accurate treatment documentation, as regulatory monitoring continues to verify compliance.

General tolerability of ceftiofur intramammary infusion in lactating dairy cattle is favorable when administered according to labeled specifications. The localized nature of intramammary delivery limits systemic absorption and correspondingly reduces potential for systemic adverse effects. Most treated cows tolerate the infusion process and treatment course without complications beyond those attributable to the underlying mastitis infection itself. Clinical trials supporting product approval and subsequent commercial experience have established a robust safety profile for this third-generation cephalosporin formulation. However, potential adverse effects must be recognized to ensure appropriate monitoring and response if complications develop.

Common side effects following lactating cow intramammary therapy with ceftiofur are generally mild and often difficult to distinguish from the course of the underlying mastitis being treated. Continued or worsening udder inflammation during treatment may reflect disease progression rather than drug adverse effect, though failure to improve suggests potential resistant organisms or need for alternative therapeutic approaches. Local tissue reaction at the infusion site may manifest as transient discomfort or swelling. Changes in milk character typically improve as infection resolves; persistence of abnormalities beyond expected recovery timeframes warrants clinical reassessment. The relatively brief treatment course of most ceftiofur intramammary protocols limits cumulative exposure that might contribute to local tissue effects.

Injection site reactions specific to intramammary infusion can include localized inflammation of teat canal or cistern tissues. The once-daily dosing schedule of ceftiofur intramammary therapy reduces the cumulative trauma from repeated cannula insertion compared to products requiring administration at every milking. However, proper partial-insertion technique remains important to minimize tissue damage with each administration. Forceful insertion or full-depth cannula placement can cause teat canal injury affecting natural defense mechanisms. Observation between treatments helps identify any progressive reaction requiring intervention. Chemical irritation from formulation components is uncommon but possible.

Serious adverse effects from ceftiofur lactating cow intramammary therapy are uncommon but warrant awareness for appropriate response. Anaphylactic reactions to beta-lactam antibiotics including cephalosporins, while rare in cattle, can occur and may be life-threatening. Signs of severe hypersensitivity include rapid onset of respiratory distress, weakness, collapse, urticaria, or edema. Such reactions require immediate veterinary attention and epinephrine administration. Cross-reactivity with penicillin allergy should be considered in animals with documented beta-lactam hypersensitivity. Severe progression of mastitis despite appropriate therapy may occur with highly virulent infections or resistant organisms and reflects disease course rather than drug adverse effect.

Species-specific toxicity considerations for ceftiofur in cattle relate primarily to the general beta-lactam hypersensitivity potential and the specific properties of third-generation cephalosporins. Systemic toxicity from ceftiofur is rare given its wide safety margin and limited systemic absorption following intramammary administration. The cephalosporin class has minimal nephrotoxicity compared to aminoglycosides, though theoretical concerns exist with any antibiotic capable of tubular secretion. Disruption of normal flora leading to superinfection with resistant organisms or yeast remains a possibility with any broad-spectrum antibiotic therapy. Documentation and reporting of any unexpected adverse events supports ongoing pharmacovigilance and appropriate product use guidance.

Species restrictions for ceftiofur intramammary products limit approved use to dairy cattle specifically for treatment of clinical mastitis during lactation. The product should not be administered to beef cattle, sheep, goats, or other livestock species without specific veterinary direction within a valid veterinarian-client-patient relationship, and even then, appropriate withdrawal considerations and antimicrobial stewardship concerns apply. The formulation and dosing are designed specifically for the lactating bovine mammary gland and are not appropriate for dry cow therapy or non-mammary administration routes. Use in animals with known hypersensitivity to cephalosporins or penicillins is contraindicated due to potential cross-reactivity within the beta-lactam antibiotic class.

Production stage considerations distinguish lactating cow products from dry cow formulations. Spectramast LC is specifically formulated for use during active lactation and should not be substituted for dry cow therapy products at the end of lactation. The pharmacokinetic properties and dosing regimen are designed for animals undergoing regular milking with associated drug clearance, not the static mammary environment of the dry period. Dry cow products conversely should not be used in lactating cows due to their extended-release formulations and different withdrawal specifications. Pregnant lactating cows can receive treatment; pregnancy does not contraindicate mastitis therapy when clinically indicated.

Age restrictions do not specifically limit ceftiofur intramammary use in lactating cattle, as the product is indicated for cows of any age presenting with clinical mastitis during lactation. First-lactation heifers and mature cows receive the same per-quarter dosing. Treatment decisions should consider the individual animal's mastitis history and the herd pathogen profile. The underlying mastitis epidemiology may differ between age groups, with younger animals potentially having different pathogen distributions than older herdmates. Young calves are not candidates for intramammary therapy as they do not have functional lactating mammary glands requiring treatment.

Disease state contraindications require careful consideration given the critically important antimicrobial status of third-generation cephalosporins. Use of ceftiofur for mastitis caused by organisms susceptible to narrower-spectrum alternatives represents suboptimal antimicrobial stewardship. Treatment of mastitis caused by methicillin-resistant staphylococci is contraindicated as these organisms are resistant to all beta-lactam antibiotics including ceftiofur. Mastitis caused by mycoplasma species, yeast, or algae does not respond to cephalosporin therapy and requires alternative management. Routine prophylactic use in the absence of clinical disease is contraindicated. Selection pressure from broad-spectrum antibiotic use contributes to resistance emergence affecting both animal and human health.

Important drug class interactions involving ceftiofur relate to the pharmacological properties of cephalosporin antibiotics and potential interactions with concurrent therapeutic agents. Theoretical antagonism exists between bactericidal antibiotics like ceftiofur and bacteriostatic agents that inhibit bacterial growth required for cell wall-targeting antibiotic activity. The clinical significance of this interaction in bovine mastitis therapy is debated. Concurrent use of multiple intramammary antibiotic products in the same quarter is generally avoided to prevent potential incompatibility and because such combinations lack safety and efficacy documentation. Nephrotoxic drugs administered systemically concurrent with intramammary cephalosporin therapy warrant monitoring, though systemic absorption from intramammary administration is limited.

Ionophore interactions represent important safety considerations in cattle management. Ionophore feed additives including monensin, lasalocid, and salinomycin are commonly incorporated into dairy cattle rations. Known toxic ionophore interactions involve primarily certain macrolide antibiotics and pleuromutilins rather than cephalosporin compounds. Direct pharmacological interaction between ionophores and intramammary ceftiofur has not been established. However, cattle receiving ionophore-containing rations who develop mastitis requiring treatment should have complete medication status documented as part of comprehensive health management and withdrawal tracking.

Feed additive interactions encompass the various supplements, medications, and performance compounds incorporated into lactating cow nutrition programs. Lactating cows receive carefully balanced rations potentially including rumen modifiers, buffers, trace minerals, and various supplements. While direct interactions with intramammary ceftiofur are not established, documentation of all products administered to treated animals supports comprehensive management. Any feed-grade antimicrobials have their own withdrawal requirements to coordinate with mastitis therapy tracking. The zero milk discard feature of ceftiofur intramammary therapy does not eliminate the need for careful attention to all sources of potential residues.

Vaccine interactions with lactating cow antibiotic therapy deserve consideration regarding timing and efficacy. Vaccination of cows undergoing active mastitis treatment is common practice, though disease stress could theoretically affect immune response development. Where practical, vaccination might be deferred until recovery from active clinical mastitis. Modified live vaccines may be more affected by concurrent illness and treatment than killed products. Systematic vaccine programs for diseases including coliform mastitis, respiratory pathogens, or reproductive diseases follow schedules that do not require specific separation from intramammary antibiotic use but should be documented. Concurrent administration of systemic anti-inflammatory drugs or supportive therapy is common and appropriate for clinical mastitis management.

Human safety considerations for handlers of ceftiofur intramammary products include awareness of potential allergic reactions and antimicrobial exposure. Individuals with known hypersensitivity to cephalosporins or penicillins should avoid direct contact with the product and should not administer intramammary therapy without appropriate protective measures. Cross-reactivity between penicillins and cephalosporins occurs in a small percentage of allergic individuals, so those with penicillin allergy should exercise caution. Beta-lactam allergy in humans ranges from mild skin reactions to severe anaphylaxis, and sensitization can develop through repeated exposure. Wearing disposable gloves during product handling and administration reduces direct exposure. Any accidental self-administration requires immediate medical attention.

Food safety considerations for ceftiofur intramammary products center on the unique zero milk discard feature and its proper application. The ability to market milk during treatment applies only when the product is used exactly according to labeled specifications. Deviation from labeled use including off-label dosing, extended treatment duration, or use in species or situations not specified on the label negates the established withdrawal and requires appropriate extended withholding. Meat withdrawal times remain applicable and must be observed should treated cows require slaughter. Accurate treatment records are essential even with zero milk discard to ensure meat withdrawal compliance and support regulatory monitoring of product use patterns.

Environmental considerations include appropriate disposal of used product containers and attention to antibiotic resistance implications. Used syringes should be disposed of as pharmaceutical waste according to local regulations. The extended spectrum of third-generation cephalosporins raises particular concern regarding selection of resistant organisms in the environment and food chain. Prudent use specifically for appropriate clinical indications rather than routine or prophylactic application supports broader efforts to preserve antimicrobial efficacy. Empty cartons can typically enter general waste streams unless contaminated. Unused or expired products should be disposed of through appropriate channels rather than environmental discharge.

Resistance concerns for third-generation cephalosporins warrant particular emphasis given their designation as critically important antimicrobials for human medicine. Extended-spectrum cephalosporin-resistant organisms including ESBL-producing Enterobacteriaceae represent serious public health threats. Judicious use of ceftiofur strictly for appropriate clinical indications supports preservation of this valuable antimicrobial class. Routine use for conditions adequately addressed by narrower-spectrum alternatives, prophylactic use without clinical disease, and use for known resistant infections all represent suboptimal practices that accelerate resistance development. Herd-level antimicrobial stewardship programs should include review of ceftiofur use patterns.

Proper use to maintain efficacy encompasses appropriate case selection, administration technique, and treatment protocol adherence. Ceftiofur intramammary therapy is most appropriately reserved for clinical mastitis cases where gram-negative involvement is suspected or confirmed, or where pathogen susceptibility testing supports its selection. Strict aseptic administration prevents introduction of additional pathogens. Complete treatment according to labeled specifications ensures adequate pathogen exposure while the zero milk discard feature depends on label compliance. Documentation supports outcome evaluation and antimicrobial stewardship monitoring. Veterinary consultation for treatment selection, particularly regarding appropriate indications for extended-spectrum cephalosporin use, helps optimize both individual cow outcomes and broader antimicrobial sustainability.

Storage requirements for ceftiofur intramammary products typically specify controlled room temperature conditions, generally between 15-30°C (59-86°F), with protection from temperature extremes and direct sunlight. Specific storage requirements should be confirmed on product labeling as formulations may have particular specifications affecting stability. Storage in a clean, dry location helps maintain product integrity and antibiotic potency throughout the labeled shelf life. Products should remain in original packaging until immediately before use to protect individual syringes from physical damage and environmental contamination. The once-daily dosing schedule means products may be held overnight between daily administrations; proper storage during this interval maintains product quality.

Multi-dose vial handling does not apply to intramammary products supplied as single-dose syringes. However, proper inspection before each use is essential during the multiple-administration treatment course. Each syringe should be examined for evidence of damage including cracked barrels, displaced plungers, damaged cannula tips, or any indication of leakage. Products showing visible abnormalities should not be administered. Syringe contents should be visually inspected when possible for color changes, precipitate formation, or phase separation suggesting degradation. Products beyond labeled expiration dates should not be used. Sufficient inventory should be confirmed before initiating therapy to ensure the complete treatment course can be administered.

Disposal requirements for ceftiofur intramammary syringes address both pharmaceutical waste and physical container components. Used syringes retain residual antibiotic and should be managed as pharmaceutical waste rather than ordinary refuse. The rigid plastic barrel and cannula constitute sharps waste due to potential puncture risk during handling. Appropriate disposal includes placement in designated sharps containers or puncture-resistant receptacles designed for medical waste. Given the particular importance of extended-spectrum cephalosporins and resistance concerns, appropriate disposal that minimizes environmental antibiotic release is especially important. Empty outer cartons can typically be disposed of with general waste unless visibly contaminated. Unused or expired products should be disposed of through pharmaceutical take-back programs or approved waste contractors.

Species-specific dosing considerations for ceftiofur lactating cow mastitis therapy follow standardized protocols across all dairy cattle breeds. The standard one-syringe-per-affected-quarter dosing applies uniformly to Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and all other dairy breeds during lactation. The once-daily dosing schedule simplifies treatment logistics across operations with varied breed compositions. Individual variation in udder size and quarter capacity exists within and between breeds, potentially affecting antibiotic dilution in mammary secretions. Higher-producing cows generating greater milk volume may experience more rapid dilution, though the pharmacokinetic properties of ceftiofur and established dosing recommendations account for this variation within the typical production range.

Breed sensitivities to ceftiofur have not been documented to differ among dairy cattle breeds when the product is administered as labeled. Holstein, Jersey, Brown Swiss, Guernsey, and other dairy breeds demonstrate comparable safety and efficacy. Individual animal hypersensitivity to beta-lactam antibiotics can occur in any breed but represents an individual rather than breed-characteristic phenomenon. Cross-reactivity with penicillin allergy should be considered in animals with documented hypersensitivity to any beta-lactam compound regardless of breed. Channel Island breeds are not recognized to have elevated cephalosporin sensitivity. Any breed-related differences in mastitis incidence reflect management and environmental factors rather than differential drug response.

Production type considerations distinguish dairy cattle managed for milk production from beef cattle not typically subject to mastitis therapy. Ceftiofur intramammary products are specifically formulated for lactating dairy cows and are not indicated for beef cattle use. The zero milk discard feature provides particular value for high-producing cows where conventional treatment would result in substantial discard of valuable milk. Within dairy production, breed differences in typical production level affect the economic impact of conventional therapy withdrawal, making the zero discard feature of ceftiofur particularly valuable in high-producing herds regardless of specific breed composition.

Age and weight considerations for lactating cow mastitis therapy relate to production stage and clinical presentation rather than absolute animal dimensions. First-lactation heifers experiencing clinical mastitis receive the same per-quarter dosing as mature cows. Coliform mastitis, a primary target indication for ceftiofur, may have different incidence patterns related to immunity development across lactations. Older cows with multiple lactations may have accumulated tissue damage affecting response. Individual history should inform treatment expectations regardless of age. The decision to use extended-spectrum cephalosporin therapy should be based on clinical indication and pathogen considerations rather than animal age or production level.

Same-class alternatives to ceftiofur for lactating cow mastitis therapy include other cephalosporin antibiotics with intramammary formulations. Cephapirin sodium represents a first-generation cephalosporin option with good gram-positive coverage though more limited gram-negative activity compared to third-generation compounds. The choice between cephalosporin generations should reflect the specific pathogen involved or suspected, with narrower-spectrum options preferred when gram-positive organisms are identified to support antimicrobial stewardship. The extended-spectrum activity of ceftiofur specifically addresses coliform mastitis that first-generation products may not adequately treat.

Different mechanism alternatives expand therapeutic options beyond cephalosporin antibiotics. Aminopenicillins including amoxicillin and hetacillin provide beta-lactam activity through traditional penicillin mechanisms with modest gram-negative extension. Pirlimycin hydrochloride offers lincosamide-class protein synthesis inhibition for gram-positive coverage. For specifically diagnosed infections requiring targeted therapy, veterinary consultation identifies appropriate alternatives. Non-antibiotic supportive care including frequent stripping, anti-inflammatory therapy, and fluid support represents critical components of severe mastitis management, particularly for coliform cases where supportive care may be as important as antimicrobial therapy.

Combination products and integrated treatment protocols address the complexity of clinical mastitis management. Systemic anti-inflammatory drugs such as flunixin meglumine or meloxicam are commonly administered concurrent with intramammary therapy to address inflammation and systemic effects, particularly important in severe coliform mastitis. Systemic antibiotic therapy may be combined with intramammary treatment for severe cases showing systemic involvement. Intravenous fluid therapy, calcium supplementation, and nursing care complement antimicrobial treatment for clinically ill cows. The integrated approach addressing both pathogen elimination and host support optimizes outcomes. Treatment selection within this integrated approach should favor the narrowest effective antimicrobial spectrum consistent with clinical presentation and pathogen identification.